Lineage Cell Therapeutics, Inc.
LCTXUS売上高
$15M
百万USD
営業利益
$-37M
百万USD
純利益
$-64M
百万USD
ROE
-142.6%
最新FY
EPS
$-0.28
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | - | $-1M | $-0.01 |
| FY2021 | Q2 | - | $-5M | $-0.03 |
| FY2021 | Q3 | - | $-8M | $-0.05 |
| FY2021 | FY | $4M | $-43M | - |
| FY2022 | Q1 | - | $-7M | $-0.04 |
| FY2022 | Q2 | - | $-7M | $-0.04 |
| FY2022 | Q3 | - | $-6M | $-0.04 |
| FY2022 | FY | $15M | $-26M | - |
| FY2023 | Q1 | - | $-4M | $-0.03 |
| FY2023 | Q2 | - | $-5M | $-0.03 |
| FY2023 | Q3 | $1M | $-7M | $-0.04 |
| FY2023 | FY | $9M | $-21M | $-0.12 |
| FY2024 | Q1 | $1M | $-7M | $-0.04 |
| FY2024 | Q2 | $1M | $-6M | $-0.03 |
| FY2024 | Q3 | $4M | $-3M | $-0.02 |
| FY2024 | FY | $9M | $-19M | $-0.09 |
| FY2025 | Q1 | $2M | $-4M | $-0.02 |
| FY2025 | Q2 | $3M | $-30M | $-0.13 |
| FY2025 | Q3 | $4M | $-30M | $-0.13 |
| FY2025 | FY | $15M | $-64M | $-0.28 |
| FY2026 | Q1 | $2M | $-5M | $-0.03 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $5M | $4M | $2M | $4M | $15M | $9M | $9M | $15M |
| 営業利益 | $-59M | $-39M | $-42M | $-39M | $-26M | $-49M | $-23M | $-25M | $-21M | $-37M |
| 純利益 | $34M | $-20M | $-46M | $-12M | $-21M | $-43M | $-26M | $-21M | $-19M | $-64M |
| 総資産 | $143M | $173M | $102M | $125M | $108M | $175M | $124M | $101M | $113M | $113M |
| 純資産 | $131M | $164M | $92M | $111M | $95M | $91M | $72M | $62M | $77M | $43M |
| 自己資本 | $118M | $163M | $94M | $113M | $96M | $92M | $73M | $63M | $78M | $45M |
| 営業CF | - | $-31M | $-31M | $-32M | $-20M | $-24M | $1M | $-29M | $-23M | $-19M |
| EPS | $0.34 | $-0.17 | - | - | - | - | - | $-0.12 | $-0.09 | $-0.28 |
| BPS | $1.06 | $1.28 | $0.63 | $0.75 | $0.60 | $0.54 | $0.43 | $0.34 | $0.34 | $0.18 |
| ROE | 28.5% | -12.3% | -49.0% | -10.4% | -21.5% | -46.6% | -35.8% | -33.9% | -23.7% | -142.6% |